Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer

Institut de Cancérologie de Lorraine30 enrolled

Overview

The objective of this study is to optimize the search by next-generation sequencing (NGS) mutations in the KRAS, BRAF and NRAS on circulating tumor DNA and compare the genetic profiles obtained with those from tumors embedded in paraffin

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Metastatic Colorectal Cancer

Interventions

KRAS, NRAS et BRAF mutation analysis from circulating plasma DNAOTHER

10 ml blood sample

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with metastatic or locally advanced colorectal carcinoma with a KRAS, BRAF or NRAS mutation * Age ≥ 18 years * Patient information and written informed consent form signed * Patient must be affiliated to a social security system Exclusion Criteria: * Patients whose health-cons indicates a blood sample 10mL * Age \< 18 years * Pregnant or breast feeding females * Persons deprived of liberty or under supervision

Locations (1)

Institut de Cancerologie de Lorraine

Vandœuvre-lès-Nancy, France

Outcomes

Primary Outcomes

Technical Optimization of KRAS, BRAF and NRAS mutations detection

Optimize the detection of mutations of KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAf (exon 15) genes, using the next-generation sequencing technology from circulating tumor DNA in patients with metastatic colorectal cancer.

Time frame: 1 day

Secondary Outcomes

KRAS, NRAS et BRAF mutational status

Compare the results of KRAS NRAS and BRAF genes genotyping obtained from circulating tumor DNA to that achieved by the current gold standard (paraffin-embedded).

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.